Travere Therapeutic
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-02-07
- Employees
- 380
- Market Cap
- -
- Website
- http://www.travere.com
- Introduction
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age with Classical Homocystinuria (HCU)
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06431893
- Locations
- 🇺🇸
Travere Investigational Site - Virtual Site, Culver City, California, United States
🇺🇸Travere Investigational Site, Philadelphia, Pennsylvania, United States
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06247085
- Locations
- 🇺🇸
Travere Investigational Site - Virtual Site, Culver City, California, United States
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05856760
- Locations
- 🇭🇰
Travere Investigational Site, Tsuen Wan, Hong Kong
🇺🇸Travere Investigation SIte, Clifton Park, New York, United States
Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05562362
- Locations
- 🇬🇧
Travere Investigational Site, Nottingham, United Kingdom
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
- Conditions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 487
- Registration Number
- NCT05200871
- Locations
- 🇪🇸
Travere Investigational Site, Madrid, Spain
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05003986
- Locations
- 🇬🇧
Travere Investigational Site, Manchester, United Kingdom
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT03762850
- Locations
- 🇬🇧
Travere Investigational Site, London, United Kingdom
Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 371
- Registration Number
- NCT03493685
- Locations
- 🇬🇧
Travere Investigational Site, York, United Kingdom
Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03406611
- Locations
- 🇺🇸
Travere Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸Travere Investigational Site - Virtual Site, Culver City, California, United States
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
- Conditions
- Interventions
- First Posted Date
- 2017-02-02
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT03041116
- Locations
- 🇪🇸
Travere Investigational Site, Barcelona, Spain